Literature DB >> 15194236

Effects of polyvalency of glycotopes and natural modifications of human blood group ABH/Lewis sugars at the Galbeta1-terminated core saccharides on the binding of domain-I of recombinant tandem-repeat-type galectin-4 from rat gastrointestinal tract (G4-N).

Albert M Wu1, June H Wu, Jia-Hau Liu, Tanuja Singh, Sabine André, Herbert Kaltner, Hans-Joachim Gabius.   

Abstract

In our recent publication, we defined core aspects of the carbohydrate specificity of domain-I of recombinant tandem-repeat-type galectin-4 from rat gastrointestinal tract (G4-N), especially its potent interaction with the linear tetrasaccharide Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc (Ibeta1-3L). The assumed role of galectin-4 as a microvillar raft stabilizer/organizer and as a malignancy-associated factor in hepatocellular and gastrointestinal carcinomas called for further refinement of its binding specificity. Thus, the effects of polyvalency of glycotopes and natural modifications of human blood group ABH/Lewis sugars at the terminal Galbeta1-core saccharides were thoroughly examined by the enzyme-linked lectinosorbent and lectin-glycan inhibition assays. The results indicate that (a) a high-density of polyvalent Galbeta1-3/4GlcNAc (I/II), Galbeta1-3GalNAc (T) and/or GalNAcalpha1-Ser/Thr (Tn) strongly favors G4-N/glycoform binding. These glycans were up to 2.3 x 10(6), 1.4 x 10(6), 8.8 x 10(5), and 1.4 x 10(5) more active than Gal, GalNAc, monomeric I/II and T, respectively; (b) while lFuc is a poor inhibitor, its presence as alpha1-2 linked to terminal Galbeta1-containing oligosaccharides, such as H active Ibeta1-3L, markedly enhances the reactivities of these ligands; (c) when blood group A (GalNAcalpha1-) or B (Galalpha1-) determinants are attached to terminal Galbeta1-3/4GlcNAc (or Glc) oligosaccharides, the reactivities are also increased; (d) with lFucalpha1-3/4 linked to sub-terminal GlcNAc, the reactivities of these haptens are reduced; and (e) short chain Le(a)/Le(x)/Le(y) and the short chains of sialyl Le(a)/Le(x) are poor inhibitors. These distinct binding features of G4-N establish the important concept of affinity enhancement by high density polyvalencies of glycotopes (vs. multi-antennary I/II) and by introduction of an ABH key sugar to Galbeta1-terminated core glycotopes. The polyvalent ligand binding properties of G4-N may help our understanding of its crucial role for cell membrane raft stability and provide salient information for the optimal design of blocking substances such as anti-tumoral glycodendrimers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194236     DOI: 10.1016/j.biochi.2004.03.007

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  20 in total

1.  Hydrodynamic properties of human adhesion/growth-regulatory galectins studied by fluorescence correlation spectroscopy.

Authors:  Antonia Göhler; Sabine André; Herbert Kaltner; Markus Sauer; Hans-Joachim Gabius; Sören Doose
Journal:  Biophys J       Date:  2010-06-16       Impact factor: 4.033

2.  Carbohydrate specificity of an insecticidal lectin isolated from the leaves of Glechoma hederacea (ground ivy) towards mammalian glycoconjugates.

Authors:  Tanuja Singh; June H Wu; Willy J Peumans; Pierre Rougé; Els J M Van Damme; Richard A Alvarez; Ola Blixt; Albert M Wu
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

3.  Selenoglycosides in silico: ab initio-derived reparameterization of MM4, conformational analysis using histo-blood group ABH antigens and lectin docking as indication for potential of bioactivity.

Authors:  Francesco Strino; Jenn-Huei Lii; Chaitanya A K Koppisetty; Per-Georg Nyholm; Hans-Joachim Gabius
Journal:  J Comput Aided Mol Des       Date:  2010-10-26       Impact factor: 3.686

4.  Towards functional glycomics by localization of binding sites for tissue lectins: lectin histochemical reactivity for galectins during diethylstilbestrol-induced kidney tumorigenesis in male Syrian hamster.

Authors:  Sven Saussez; Francois Lorfevre; Denis Nonclercq; Guy Laurent; Sabine André; Fabrice Journé; Robert Kiss; Gérard Toubeau; Hans-Joachim Gabius
Journal:  Histochem Cell Biol       Date:  2006-01-25       Impact factor: 4.304

5.  Structural aspects of binding of α-linked digalactosides to human galectin-1.

Authors:  Michelle C Miller; João P Ribeiro; Virginia Roldós; Sonsoles Martín-Santamaría; F Javier Cañada; Irina A Nesmelova; Sabine André; Mabel Pang; Anatole A Klyosov; Linda G Baum; Jesús Jiménez-Barbero; Hans-Joachim Gabius; Kevin H Mayo
Journal:  Glycobiology       Date:  2011-06-28       Impact factor: 4.313

6.  Ganglioside GM1/galectin-dependent growth regulation in human neuroblastoma cells: special properties of bivalent galectin-4 and significance of linker length for ligand selection.

Authors:  Jürgen Kopitz; Seda Ballikaya; Sabine André; Hans-Joachim Gabius
Journal:  Neurochem Res       Date:  2012-01-11       Impact factor: 3.996

7.  Differential affinities of Erythrina cristagalli lectin (ECL) toward monosaccharides and polyvalent mammalian structural units.

Authors:  Albert M Wu; June H Wu; Ming-Sung Tsai; Zhangung Yang; Nathan Sharon; Anthony Herp
Journal:  Glycoconj J       Date:  2007-09-06       Impact factor: 2.916

Review 8.  Lectins as tools in glycoconjugate research.

Authors:  Albert M Wu; Elwira Lisowska; Maria Duk; Zhangung Yang
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

9.  Conformational analysis of thioglycoside derivatives of histo-blood group ABH antigens using an ab initio-derived reparameterization of MM4: implications for design of non-hydrolysable mimetics.

Authors:  Francesco Strino; Jenn-Huei Lii; Hans-Joachim Gabius; Per-Georg Nyholm
Journal:  J Comput Aided Mol Des       Date:  2009-09-15       Impact factor: 3.686

10.  Human tandem-repeat-type galectins bind bacterial non-βGal polysaccharides.

Authors:  Yu A Knirel; H-J Gabius; O Blixt; E M Rapoport; N R Khasbiullina; N V Shilova; N V Bovin
Journal:  Glycoconj J       Date:  2013-09-25       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.